These findings, for the first time, allude to a possible unique immunoregulatory role for the CD6 ligand CD318 in T-cell-mediated autoimmune disorders, as well as a possible novel immunological checkpoint relevant to the pathogenesis and treatment of T1D. Here, CDCP1 is linked to type 1 diabetes mellitus.